As the Supreme Court considers a case about the FDA’s regulation of mifepristone, Dean Rachel Rebouche explains how the outcome could impact not just access to abortion care but the FDA’s authority to do its job.
Published on April 11, 2024
Supreme Court seems likely to preserve access to the abortion medication mifepristone
